Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Arezzo – page 32

1 011 clinical trials in Arezzo, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Arezzo at a glance
1 011
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 011 trials in Arezzo

Open in trial search

Glomerulonephritis rapidly progressive

Recruiting

Study on the Safety and Tolerability of Lixudebart and Rituximab for Patients with Rapidly Progressive Glomerulonephritis Due to ANCA-Associated Vasculitis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Alentis Therapeutics AG

Bronchopulmonary dysplasia

Recruiting

Study on the Safety and Effect of EXOB-001 in Preventing Bronchopulmonary Dysplasia in Extremely Preterm Newborns

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Sodium Chloride
  • Sponsor:Exo Biologics

Metastatic malignant melanoma+1

Recruiting

Study of Tebentafusp and Pembrolizumab for Patients with Previously Treated Advanced Melanoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Immunocore Limited

Superficial spreading melanoma stage III

Recruiting

Study on the Effectiveness of L19IL2 and L19TNF Injections with Surgery for Patients with Stage IIIB/C Melanoma

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Onfekafusp Alfa
  • Sponsor:Philogen S.p.A.

Neoplasm malignant

Recruiting

Study of BMS-986340, Nivolumab, and Docetaxel for Adults with Advanced or Metastatic Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BMS-986340
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Plasma cell myeloma

Recruiting

Study Comparing Iberdomide and Lenalidomide for Maintenance Therapy After Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Celgene Corp.

Factor VIII deficiency

Recruiting

Study on the Use of Simoctocog Alfa and Emicizumab for Surgery in Patients with Severe Hemophilia A

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Octapharma AG

Axial spondyloarthritis+4

Recruiting

Study on Long-Term Safety of Secukinumab for Patients with Psoriatic Arthritis, Ankylosing Spondylitis, and Severe Chronic Plaque Psoriasis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG

Squamous cell carcinoma of head and neck

Recruiting

Study of Cetuximab and Avelumab for Patients with Recurrent or Metastatic Head and Neck Cancer with PD-L1 Score 1 or Higher

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Fondazione GONO Plus

Inflammatory bowel disease

Recruiting

Study on the Effectiveness of Infliximab for Children with Inflammatory Bowel Disease

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Infliximab
  • Sponsor:Istituto Di Ricovero E Cura A Carattere Scientifico Materno Infantile Burlo Garofolo

Triple negative breast cancer

Recruiting

Study of Sacituzumab Govitecan and Pembrolizumab for Patients with Triple Negative Breast Cancer with Residual Disease After Surgery and Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Gilead Sciences Inc.

Juvenile idiopathic arthritis

Recruiting

Study on Early Drug Withdrawal in Children with Juvenile Idiopathic Arthritis Using Secukinumab and Drug Combination for Those in Clinical Remission

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Abatacept
  • Sponsor:IRCCS Istituto Giannina Gaslini

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Arezzo

What the registry says about research in the country

01 Urological Oncology

Extensive research focusing on bladder cancer treatments, including innovative therapies combining immunotherapy with established treatments. Studies evaluate new approaches for both muscle-invasive and non-muscle invasive disease.

  • Bladder Cancer Immunotherapy
  • Urothelial Carcinoma Treatment
  • BCG Combination Therapies

Multiple trials exploring targeted treatments for patients with various stages of disease progression.

02 Prostate Cancer Research

Advanced studies examining new therapeutic approaches for metastatic prostate cancer, including novel drug combinations and targeted therapies for specific genetic mutations.

  • Castration-resistant Disease
  • Targeted Molecular Therapies
  • Hormone-based Treatments

Investigating innovative treatment sequences and combinations to improve patient outcomes.

03 Kidney Cancer Innovations

Cutting-edge research in renal cell carcinoma treatment, exploring immunotherapy combinations and targeted approaches for both early-stage and metastatic disease.

  • Immunotherapy Combinations
  • Targeted Molecular Agents
  • Advanced Disease Management

Focus on improving survival rates through novel therapeutic strategies.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.